US Patent Issued to National Research Council of Canada on Aug. 11 for "Anti-CD22 single domain antibodies and therapeutic constructs" (Canadian Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,703,744, issued on Aug. 11, was assigned to National Research Council of Canada (Ottawa).

"Anti-CD22 single domain antibodies and therapeutic constructs" was invented by Scott McComb (Ottawa), Risini Weeratna (Ottawa), Mehdi Arbabi-Ghahroudi (Ottawa), Tina Nguyen (Ottawa) and Cunle Wu (Montreal).

According to the abstract* released by the U.S. Patent & Trademark Office: "Herein are provided anti-CD22 single domain antibodies (sdAb) prepared by immunizing a llama with the extracellular domain of the predominant human CD22 isoform. By constructing a library of the heavy chain repertoire generated, VHH antibodies specific to the immunogen were isolated. The 27 example antibodies initial...